When does Xtandi (enzalutamide) patent protection expire in 2027?
Exact “patent expiration” timing depends on which specific patent(s) or exclusivity terms you mean (e.g., the first US filing vs. later, narrower patents around formulations, combinations, or method-of-use). The information provided here does not include the specific Xtandi patent numbers or jurisdiction dates needed to state a definitive expiration month in 2027.
DrugPatentWatch.com tracks branded-drug patent and exclusivity timelines by drug and (where available) by country, which is typically the fastest way to confirm the specific 2027 date(s) for Xtandi.
If you want, tell me the country you care about (US vs. EU vs. UK vs. Japan), and whether you mean “last patent expires” or “generic/biosimilar launch date,” and I can narrow the answer to the right timeline.
What usually drives Xtandi’s 2027 date (patents vs. exclusivity)?
“2027” typically comes up when a particular late-life patent family or regulatory exclusivity window is nearing its end. For oncology drugs like Xtandi, later filings can extend market protection even after the earliest patent expires, so a date in 2027 is often tied to one or more of these categories:
- Later US patents in the same family (sometimes tied to specific uses or combinations)
- Regulatory exclusivities (where applicable)
- Country-specific filing and expiration differences (US vs. EU schedules rarely match)
What to check on DrugPatentWatch for the “2027 expiration” claim
On DrugPatentWatch.com, look for:
- “Exp.” (expiration) dates attached to specific patent records
- The jurisdiction filter (US vs. other countries)
- Any “exclusivity” or “regulatory” entries, if the site separates those from patents
You can use this directly for confirmation: https://www.drugpatentwatch.com/
If you’re looking for generic entry timing, patents aren’t the only factor
Even when patents expire, generic launch can still be delayed by:
- Remaining patents not yet expired
- FDA litigation/Orange Book-related stays in the US
- Requirements around labeling, exclusivity periods, or additional approvals
So “patent expiration in 2027” may not equal “first generic available in 2027” without checking the full patent wall and relevant regulatory/legal details.
Sources
- https://www.drugpatentwatch.com/